Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $15.48 million. The enterprise value is -$36.81 million.
| Market Cap | 15.48M |
| Enterprise Value | -36.81M |
Important Dates
The last earnings date was Monday, October 26, 2026, before market open.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 72.33 million shares outstanding. The number of shares has increased by 11.05% in one year.
| Current Share Class | 72.33M |
| Shares Outstanding | 72.33M |
| Shares Change (YoY) | +11.05% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 14.60% |
| Owned by Institutions (%) | 35.88% |
| Float | 37.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.89 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.65 |
Financial Efficiency
Return on equity (ROE) is -162.72% and return on invested capital (ROIC) is -70.78%.
| Return on Equity (ROE) | -162.72% |
| Return on Assets (ROA) | -57.46% |
| Return on Invested Capital (ROIC) | -70.78% |
| Return on Capital Employed (ROCE) | -258.70% |
| Weighted Average Cost of Capital (WACC) | 10.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.03% in the last 52 weeks. The beta is 0.45, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -89.03% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 21.42 |
| Average Volume (20 Days) | 7,127,737 |
Short Selling Information
The latest short interest is 4.56 million, so 6.30% of the outstanding shares have been sold short.
| Short Interest | 4.56M |
| Short Previous Month | 3.09M |
| Short % of Shares Out | 6.30% |
| Short % of Float | 12.30% |
| Short Ratio (days to cover) | 1.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | -85.93M |
| Operating Income | -104.72M |
| Pretax Income | -103.96M |
| Net Income | -103.96M |
| EBITDA | -104.67M |
| EBIT | -104.72M |
| Earnings Per Share (EPS) | -$1.55 |
Balance Sheet
The company has $78.60 million in cash and $26.31 million in debt, with a net cash position of $52.29 million or $0.72 per share.
| Cash & Cash Equivalents | 78.60M |
| Total Debt | 26.31M |
| Net Cash | 52.29M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 34.61M |
| Book Value Per Share | 0.48 |
| Working Capital | 40.05M |
Cash Flow
| Operating Cash Flow | -87.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 47,000 |
| Net Borrowing | -4.99M |
| Free Cash Flow | -87.95M |
| FCF Per Share | -$1.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.05% |
| Shareholder Yield | -11.05% |
| Earnings Yield | -723.82% |
| FCF Yield | -568.24% |
Analyst Forecast
The average price target for ABOS is $1.00, which is 367.29% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 367.29% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |